Skip to main content
Erschienen in: Abdominal Radiology 11/2021

24.07.2021 | Interventional Radiology

Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt

verfasst von: Hai-lin Lu, Fei-fei Xuan, Yao-chang Luo, Xiao Qin

Erschienen in: Abdominal Radiology | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study seeks to assess the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) combined with transarterial embolization/transarterial chemoembolization (TAE/TACE) in hepatocellular carcinoma (HCC) with portal hypertension and arterioportal shunt (APS).

Methods

Consecutive hospitalized patients having HCC accompanied by portal hypertension and APS were retrospectively analyzed. A total of 103 patients were enrolled. Of them, 26 patients were in Group A and 77 patients were in Group B according to the treatment protocol (Group A: TIPS plus TAE/TACE; Group B: TAE/TACE alone). The clinical outcomes and survival rate were compared between the two groups.

Results

The mean survival time in Group A and Group B were 14 mo and 9.9 mo, respectively, with statistical difference (p = 0.043). The immediate APS improvement rate was 95.2% in Group A and 91.9% in Group B, respectively, with no signficant difference (p = 1.000). However, the first follow-up consultation revealed that APS improvement rate in Group A was more obvious (66.7% vs 27.4%, p = 0.001). Objective response rate of HCC tended to be greater in Group A compared with Group B (65.4% vs 38.7%, p = 0.019). Liver function parameters significantly increased in Group A than those in Group B. After TIPS placement, the mean portal pressure gradient decreased from 32.61 ± 8.87 mmHg to 15.61 ± 8.15 mmHg, with significant difference (p = 0.000). The rate of absorption of ascites and control of variceal bleeding were statistically different between the two groups (p = 0.045 and 0.039, respectively).

Conclusion

Our research suggests that TIPS combined with TAE/TACE seems to be safe and efficacious in patients with HCC accompanied by portal hypertension and APS, albeit may be accompanied by liver function damage.

Graphic abstract

Literatur
1.
Zurück zum Zitat Bosetti C, Turati F, La Vecchia C: Hepatocellular carcinoma epidemiology. Best practice & research Clinical gastroenterology 2014, 28(5):753-770.CrossRef Bosetti C, Turati F, La Vecchia C: Hepatocellular carcinoma epidemiology. Best practice & research Clinical gastroenterology 2014, 28(5):753-770.CrossRef
2.
Zurück zum Zitat Hartke J, Johnson M, Ghabril M: The diagnosis and treatment of hepatocellular carcinoma. Seminars in diagnostic pathology 2017, 34(2):153-159.CrossRef Hartke J, Johnson M, Ghabril M: The diagnosis and treatment of hepatocellular carcinoma. Seminars in diagnostic pathology 2017, 34(2):153-159.CrossRef
3.
Zurück zum Zitat Pillai AK, Andring B, Patel A, Trimmer C, Kalva SP: Portal hypertension: a review of portosystemic collateral pathways and endovascular interventions. Clin Radiol 2015, 70(10):1047-1059.CrossRef Pillai AK, Andring B, Patel A, Trimmer C, Kalva SP: Portal hypertension: a review of portosystemic collateral pathways and endovascular interventions. Clin Radiol 2015, 70(10):1047-1059.CrossRef
4.
Zurück zum Zitat Simonetto DA, Liu M, Kamath PS: Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc 2019, 94(4):714-726.CrossRef Simonetto DA, Liu M, Kamath PS: Portal Hypertension and Related Complications: Diagnosis and Management. Mayo Clin Proc 2019, 94(4):714-726.CrossRef
5.
Zurück zum Zitat Oh D, Shin SW, Park HC, Cho SK, Lim DH, Paik SW: Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy. Cancer research and treatment 2015, 47(2):251-258.CrossRef Oh D, Shin SW, Park HC, Cho SK, Lim DH, Paik SW: Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy. Cancer research and treatment 2015, 47(2):251-258.CrossRef
6.
Zurück zum Zitat Xiao YD, Ma C, Zhang ZS, Liu J: Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience. Cancer management and research 2019, 11:1551-1557.CrossRef Xiao YD, Ma C, Zhang ZS, Liu J: Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience. Cancer management and research 2019, 11:1551-1557.CrossRef
7.
Zurück zum Zitat Kim JH, Sinn DH, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW: Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. Digestive diseases and sciences 2016, 61(11):3354-3362.CrossRef Kim JH, Sinn DH, Kim K, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW: Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. Digestive diseases and sciences 2016, 61(11):3354-3362.CrossRef
8.
Zurück zum Zitat Hsu CY, Lee YH, Huang YH, Hsia CY, Su CW, Lin HC, Lee RC, Chiou YY, Lee FY, Huo TI et al: Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatology international 2013, 7(1):188-198.CrossRef Hsu CY, Lee YH, Huang YH, Hsia CY, Su CW, Lin HC, Lee RC, Chiou YY, Lee FY, Huo TI et al: Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatology international 2013, 7(1):188-198.CrossRef
9.
Zurück zum Zitat Zheng YW, Wang KP, Zhou JJ, Zhang ZQ, Xiong L, Wen Y, Zou H: Portal hypertension predicts short-term and long-term outcomes after hepatectomy in hepatocellular carcinoma patients. Scandinavian journal of gastroenterology 2018, 53(12):1562-1568.CrossRef Zheng YW, Wang KP, Zhou JJ, Zhang ZQ, Xiong L, Wen Y, Zou H: Portal hypertension predicts short-term and long-term outcomes after hepatectomy in hepatocellular carcinoma patients. Scandinavian journal of gastroenterology 2018, 53(12):1562-1568.CrossRef
10.
Zurück zum Zitat EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of hepatology 2018, 69(2):406–460. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of hepatology 2018, 69(2):406–460.
11.
Zurück zum Zitat Hung ML, Lee EW: Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension: Review and Update of the Literature. Clinics in liver disease 2019, 23(4):737-754.CrossRef Hung ML, Lee EW: Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension: Review and Update of the Literature. Clinics in liver disease 2019, 23(4):737-754.CrossRef
12.
Zurück zum Zitat Kikolski SG, Aryafar H, Rose SC, Roberts AC, Kinney TB: Transjugular intrahepatic portosystemic shunt for treatment of cirrhosis-related chylothorax and chylous ascites: single-institution retrospective experience. Cardiovascular and interventional radiology 2013, 36(4):992-997.CrossRef Kikolski SG, Aryafar H, Rose SC, Roberts AC, Kinney TB: Transjugular intrahepatic portosystemic shunt for treatment of cirrhosis-related chylothorax and chylous ascites: single-institution retrospective experience. Cardiovascular and interventional radiology 2013, 36(4):992-997.CrossRef
13.
Zurück zum Zitat Bonnel AR, Bunchorntavakul C, Rajender Reddy K: Transjugular intrahepatic portosystemic shunts in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2014, 20(2):130-139.CrossRef Bonnel AR, Bunchorntavakul C, Rajender Reddy K: Transjugular intrahepatic portosystemic shunts in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2014, 20(2):130-139.CrossRef
14.
Zurück zum Zitat Jiang Q, Wang MQ, Zhang GB, Wu Q, Xu JM, Kong DR: Transjugular intrahepatic portosystemic shunt combined with esophagogastric variceal embolization in the treatment of a large gastrorenal shunt. World journal of hepatology 2016, 8(20):850-857.CrossRef Jiang Q, Wang MQ, Zhang GB, Wu Q, Xu JM, Kong DR: Transjugular intrahepatic portosystemic shunt combined with esophagogastric variceal embolization in the treatment of a large gastrorenal shunt. World journal of hepatology 2016, 8(20):850-857.CrossRef
15.
Zurück zum Zitat Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet (London, England) 2012, 379(9822):1245-1255.CrossRef Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet (London, England) 2012, 379(9822):1245-1255.CrossRef
16.
Zurück zum Zitat Murata S, Tajima H, Nakazawa K, Onozawa S, Kumita S, Nomura K: Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts. European radiology 2009, 19(8):2016-2023.CrossRef Murata S, Tajima H, Nakazawa K, Onozawa S, Kumita S, Nomura K: Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts. European radiology 2009, 19(8):2016-2023.CrossRef
17.
Zurück zum Zitat Miura JT, Gamblin TC: Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. Surgical oncology clinics of North America 2015, 24(1):149-166.CrossRef Miura JT, Gamblin TC: Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. Surgical oncology clinics of North America 2015, 24(1):149-166.CrossRef
18.
Zurück zum Zitat Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan RK, Jr.: Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol 2013, 24(1):68-73.CrossRef Kohi MP, Fidelman N, Naeger DM, LaBerge JM, Gordon RL, Kerlan RK, Jr.: Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol 2013, 24(1):68-73.CrossRef
19.
Zurück zum Zitat Ruohoniemi DM, Taslakian B, Aaltonen EA, Hickey R, Patel A, Horn JC, Chiarello M, McDermott M: Comparative Analysis of Safety and Efficacy of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma in Patients with and without Pre-Existing Transjugular Intrahepatic Portosystemic Shunts. J Vasc Interv Radiol 2020, 31(3):409-415.CrossRef Ruohoniemi DM, Taslakian B, Aaltonen EA, Hickey R, Patel A, Horn JC, Chiarello M, McDermott M: Comparative Analysis of Safety and Efficacy of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma in Patients with and without Pre-Existing Transjugular Intrahepatic Portosystemic Shunts. J Vasc Interv Radiol 2020, 31(3):409-415.CrossRef
20.
Zurück zum Zitat Li J, Kang X, Guo L, Xiao J, Cheng J: Embolization of hepatic arterioportal shunt with ethanol-soaked gelatin sponge. J Cancer Res Ther 2019, 15(2):336-340.PubMed Li J, Kang X, Guo L, Xiao J, Cheng J: Embolization of hepatic arterioportal shunt with ethanol-soaked gelatin sponge. J Cancer Res Ther 2019, 15(2):336-340.PubMed
21.
Zurück zum Zitat Shi HB, Yang ZQ, Liu S, Zhou WZ, Zhou CG, Zhao LB, Xia JG, Li LS: Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013, 36(2):412-421.CrossRef Shi HB, Yang ZQ, Liu S, Zhou WZ, Zhou CG, Zhao LB, Xia JG, Li LS: Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013, 36(2):412-421.CrossRef
22.
Zurück zum Zitat Kumar R, Kerbert AJC, Sheikh MF, Roth N, Calvao JAF, Mesquita MD, Barreira AI, Gurm HS, Ramsahye K, Mookerjee RP et al: Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding. Journal of hepatology 2020. Kumar R, Kerbert AJC, Sheikh MF, Roth N, Calvao JAF, Mesquita MD, Barreira AI, Gurm HS, Ramsahye K, Mookerjee RP et al: Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding. Journal of hepatology 2020.
23.
Zurück zum Zitat Qi X, He C, Guo W, Yin Z, Wang J, Wang Z, Niu J, Bai M, Yang Z, Fan D et al: Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. Liver international : official journal of the International Association for the Study of the Liver 2016, 36(5):667-676.CrossRef Qi X, He C, Guo W, Yin Z, Wang J, Wang Z, Niu J, Bai M, Yang Z, Fan D et al: Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. Liver international : official journal of the International Association for the Study of the Liver 2016, 36(5):667-676.CrossRef
24.
Zurück zum Zitat Yan H, Wang G, Zhu W, Feng K, Zhu W, Wu X, Qiu Z, Chen G, Jiang W, Zhang F et al: Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites. Translational oncology 2020, 13(12):100864. Yan H, Wang G, Zhu W, Feng K, Zhu W, Wu X, Qiu Z, Chen G, Jiang W, Zhang F et al: Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites. Translational oncology 2020, 13(12):100864.
25.
Zurück zum Zitat Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Jr., Fidelman N: Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovascular and interventional radiology 2013, 36(5):1336-1343.CrossRef Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Jr., Fidelman N: Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovascular and interventional radiology 2013, 36(5):1336-1343.CrossRef
26.
Zurück zum Zitat Knüppel E, Bettinger D, Euringer W, Thimme R, Roessle M, Spangenberg HC, Schultheiβ M: Influence of the transjugular intrahepatic portosystemic stent on firstline treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md) 2013, 58(6):2211-2212.CrossRef Knüppel E, Bettinger D, Euringer W, Thimme R, Roessle M, Spangenberg HC, Schultheiβ M: Influence of the transjugular intrahepatic portosystemic stent on firstline treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md) 2013, 58(6):2211-2212.CrossRef
27.
Zurück zum Zitat Qiu B, Li K, Dong X, Liu FQ: Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovascular and interventional radiology 2017, 40(9):1372-1382.CrossRef Qiu B, Li K, Dong X, Liu FQ: Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovascular and interventional radiology 2017, 40(9):1372-1382.CrossRef
28.
Zurück zum Zitat Zhao JB, Feng C, Zhu QH, He XF, Li YH, Chen Y: Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis. World journal of gastroenterology 2014, 20(6):1602-1607.CrossRef Zhao JB, Feng C, Zhu QH, He XF, Li YH, Chen Y: Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis. World journal of gastroenterology 2014, 20(6):1602-1607.CrossRef
29.
Zurück zum Zitat Luo J, Li M, Wu C, Zhu D, Wang H, Huang M, Jiang Z: Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria. European journal of gastroenterology & hepatology 2020. Luo J, Li M, Wu C, Zhu D, Wang H, Huang M, Jiang Z: Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria. European journal of gastroenterology & hepatology 2020.
30.
Zurück zum Zitat Weidekamm C, Cejna M, Kramer L, Peck-Radosavljevic M, Bader TR: Effects of TIPS on liver perfusion measured by dynamic CT. AJR American journal of roentgenology 2005, 184(2):505-510.CrossRef Weidekamm C, Cejna M, Kramer L, Peck-Radosavljevic M, Bader TR: Effects of TIPS on liver perfusion measured by dynamic CT. AJR American journal of roentgenology 2005, 184(2):505-510.CrossRef
31.
Zurück zum Zitat Stankovic Z, Rössle M, Euringer W, Schultheiss M, Salem R, Barker A, Carr J, Langer M, Markl M, Collins JD: Effect of TIPS placement on portal and splanchnic arterial blood flow in 4-dimensional flow MRI. European radiology 2015, 25(9):2634-2640.CrossRef Stankovic Z, Rössle M, Euringer W, Schultheiss M, Salem R, Barker A, Carr J, Langer M, Markl M, Collins JD: Effect of TIPS placement on portal and splanchnic arterial blood flow in 4-dimensional flow MRI. European radiology 2015, 25(9):2634-2640.CrossRef
32.
Zurück zum Zitat Liu L, Zhao Y, Qi X, Cai G, He C, Guo W, Yin Z, Chen H, Chen X, Fan D et al: Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis. Hepatology research : the official journal of the Japan Society of Hepatology 2014, 44(6):621-630.CrossRef Liu L, Zhao Y, Qi X, Cai G, He C, Guo W, Yin Z, Chen H, Chen X, Fan D et al: Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis. Hepatology research : the official journal of the Japan Society of Hepatology 2014, 44(6):621-630.CrossRef
33.
Zurück zum Zitat Jiang ZB, Shan H, Shen XY, Huang MS, Li ZR, Zhu KS, Guan SH: Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis. World journal of gastroenterology 2004, 10(13):1881-1884.CrossRef Jiang ZB, Shan H, Shen XY, Huang MS, Li ZR, Zhu KS, Guan SH: Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis. World journal of gastroenterology 2004, 10(13):1881-1884.CrossRef
34.
Zurück zum Zitat Bettinger D, Knüppel E, Euringer W, Spangenberg HC, Rössle M, Thimme R, Schultheiß M: Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. Alimentary pharmacology & therapeutics 2015, 41(1):126-136.CrossRef Bettinger D, Knüppel E, Euringer W, Spangenberg HC, Rössle M, Thimme R, Schultheiß M: Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. Alimentary pharmacology & therapeutics 2015, 41(1):126-136.CrossRef
35.
Zurück zum Zitat Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ: Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World journal of gastroenterology 2015, 21(43):12439-12447.CrossRef Qiu B, Zhao MF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Dai S, Yao JN, Liu FQ: Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World journal of gastroenterology 2015, 21(43):12439-12447.CrossRef
36.
Zurück zum Zitat Luo SH, Chu JG, Huang H, Yao KC: Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. World journal of clinical cases 2019, 7(13):1599-1610.CrossRef Luo SH, Chu JG, Huang H, Yao KC: Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. World journal of clinical cases 2019, 7(13):1599-1610.CrossRef
37.
Zurück zum Zitat Dariushnia SR, Haskal ZJ, Midia M, Martin LG, Walker TG, Kalva SP, Clark TW, Ganguli S, Krishnamurthy V, Saiter CK et al: Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts. Journal of vascular and interventional radiology : JVIR 2016, 27(1):1-7.CrossRef Dariushnia SR, Haskal ZJ, Midia M, Martin LG, Walker TG, Kalva SP, Clark TW, Ganguli S, Krishnamurthy V, Saiter CK et al: Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts. Journal of vascular and interventional radiology : JVIR 2016, 27(1):1-7.CrossRef
38.
Zurück zum Zitat Routhu M, Safka V, Routhu SK, Fejfar T, Jirkovsky V, Krajina A, Cermakova E, Hosak L, Hulek P: Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS). Annals of hepatology 2017, 16(1):140-148.CrossRef Routhu M, Safka V, Routhu SK, Fejfar T, Jirkovsky V, Krajina A, Cermakova E, Hosak L, Hulek P: Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS). Annals of hepatology 2017, 16(1):140-148.CrossRef
39.
Zurück zum Zitat Coronado WM, Ju C, Bullen J, Kapoor B: Predictors of Occurrence and Risk of Hepatic Encephalopathy After TIPS Creation: A 15-Year Experience. Cardiovascular and interventional radiology 2020, 43(8):1156-1164.CrossRef Coronado WM, Ju C, Bullen J, Kapoor B: Predictors of Occurrence and Risk of Hepatic Encephalopathy After TIPS Creation: A 15-Year Experience. Cardiovascular and interventional radiology 2020, 43(8):1156-1164.CrossRef
40.
Zurück zum Zitat Yao J, Zuo L, An G, Yue Z, Zhao H, Wang L, Liu F: Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension. Journal of gastrointestinal and liver diseases : JGLD 2015, 24(3):301-307.CrossRef Yao J, Zuo L, An G, Yue Z, Zhao H, Wang L, Liu F: Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension. Journal of gastrointestinal and liver diseases : JGLD 2015, 24(3):301-307.CrossRef
41.
Zurück zum Zitat Perello MP, Mur JP, Vives MS, Riutort JMM, Artigues AP, Garcia CN, Vidal MLB, Gelabert AE, Garau MV: Long-term follow-up of transjugular intrahepatic portosystemic shunt (TIPS) with stent-graft. Diagnostic and interventional radiology (Ankara, Turkey) 2019, 25(5):346-352.CrossRef Perello MP, Mur JP, Vives MS, Riutort JMM, Artigues AP, Garcia CN, Vidal MLB, Gelabert AE, Garau MV: Long-term follow-up of transjugular intrahepatic portosystemic shunt (TIPS) with stent-graft. Diagnostic and interventional radiology (Ankara, Turkey) 2019, 25(5):346-352.CrossRef
42.
Zurück zum Zitat Wan YM, Li YH, Xu Y, Wu HM, Li YC, Wu XN, Yang JH: Predictors of Shunt Dysfunction and Overall Survival in Patients with Variceal Bleeding Treated with Transjugular Portosystemic Shunt Creation Using the Fluency Stent Graft. Academic radiology 2018, 25(7):925-934.CrossRef Wan YM, Li YH, Xu Y, Wu HM, Li YC, Wu XN, Yang JH: Predictors of Shunt Dysfunction and Overall Survival in Patients with Variceal Bleeding Treated with Transjugular Portosystemic Shunt Creation Using the Fluency Stent Graft. Academic radiology 2018, 25(7):925-934.CrossRef
Metadaten
Titel
Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt
verfasst von
Hai-lin Lu
Fei-fei Xuan
Yao-chang Luo
Xiao Qin
Publikationsdatum
24.07.2021
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 11/2021
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-03214-5

Weitere Artikel der Ausgabe 11/2021

Abdominal Radiology 11/2021 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.